Faculty Opinions recommendation of Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy.

Authors:

Abstract
Heart failure is a major condition associated with ageing. As we age, the contractile cells in the heart -- the cardiomyocytes -- undergo hypertrophic growth and our heart increases in size. This growth eventually leads to impaired relaxation and refilling of the heart during diastole, and to heart failure. In contrast to systolic dysfunction, which affects cardiac contraction, few treatments have succeeded at improving diastolic dysfunction. In this landmark study, Loffredo and colleagues show that factors in the circulation of young mice can reverse age-related cardiac hypertrophy. The authors connected the circulatory system of an old mouse to that of a young mouse, an intervention known as parabiosis, to allow the exchange of blood. After four weeks, old mice connected to young mice showed a reduction in the size of both individual cardiomyocytes and the whole heart. This reduction was unrelated to changes in blood pressure or behaviour. Proteomic analysis showed an increase in growth differentiation factor 11 (GDF11) in the blood of young mice. GDF11, a growth factor of the TGF-beta family, is produced mainly in the spleen and its production decreases with age. Treatment of cardiomyocytes in culture with this factor activated SMADs and FoxO factors and reduced hypertrophy. Administration of GDF11 to old mice recapitulated the response to young mouse blood factors, reducing both cardiac hypertrophy and the expression of heart failure markers. Interestingly, GDF11 had no effect on cardiac hypertrophy induced by pressure overload in a mouse model of aortic stenosis, suggesting that this treatment may be most effective in old animals that already show a decrease in GDF11 expression. This study shows that age-related cardiac hypertrophy is also a systemic disease and shows that GDF11 may be an interesting therapeutic option for this condition.